Hair Loss & Restoration and Exosomes and extracellular vesicles: what the trial registry contains
The ClinicalTrials.gov registry holds 10 records for exosomes in Hair Loss & Restoration: 3 recruiting now, 1 labelled Phase 3 or 4, across 6 countries. Snapshot 2026-08-29.
Why this is studied in Hair Loss & Restoration
Androgenetic alopecia is a hormone-driven miniaturisation of follicles, not follicle death, which is why regenerative approaches are biologically plausible: the target still exists. It is also the one tracked indication where exosome registrations outnumber whole-cell studies, reflecting how quickly aesthetic markets adopt cell-free products.
What exosomes means in this table
Exosome and extracellular-vesicle products are cell-free: vesicles harvested from cultured cells and given without the cells themselves. They are attractive commercially because they avoid live-cell logistics, and they are regulatorily contested for the same reason — several regulators have issued explicit warnings about unapproved exosome products marketed for human use.
The numbers
Every figure below comes from one reproducible query (androgenetic alopecia x exosome) run against ClinicalTrials.gov API v2 on 2026-08-29.
| Metric | Value |
|---|---|
| Registered studies (all statuses) | 10 |
| Interventional studies in the sample | 10 |
| Recruiting right now | 3 |
| Completed | 3 |
| Terminated, withdrawn or suspended | 0 |
| Phase 3 or Phase 4 records | 1 |
| Countries with at least one site | 6 |
| Median planned enrolment | 35 participants |
| Largest single planned enrolment | 120 participants |
| First / most recent start year | 2023 — 2026 |
How mature is this evidence?
The field has produced some later-stage designs — 1 of the 10 records carry a Phase 3 or 4 label — but the bulk of activity remains earlier-phase safety and signal-finding work.
The delivery record matters as much as the count: 3 completed against 0 abandoned or suspended, or 0% of everything registered.
| Phase label | Records | Share |
|---|---|---|
| Phase 2 | 4 | 33% |
| Not applicable | 4 | 33% |
| Phase 1 | 3 | 25% |
| Phase 3 | 1 | 8% |
Median planned enrolment is 35 participants (largest single study: 120). Trials of this size can describe safety and generate hypotheses; detecting a modest clinical benefit reliably usually needs substantially larger numbers with a control group.
Where the studies are
Sites are spread across 6 countries, with China accounting for roughly 40% of country mentions — geography reflects where regulators permit this work and where sponsors sit, not where care is best.
| Country | Studies with a site there |
|---|---|
| China | 4 |
| Egypt | 2 |
| Pakistan | 1 |
| Turkey (Türkiye) | 1 |
| United States | 1 |
| Taiwan | 1 |
Legal pathway differs by country — see where cell therapy is legal, by country.
Who runs them
Funding profile: 4 academic or hospital sponsors against 2 commercial ones — academic overall, which is worth knowing before reading any single positive report.
- Zhang Han — 1 record
- Fujian Medical University Union Hospital — 1 record
- Services Hospital, Lahore — 1 record
- Yeditepe University Hospital — 1 record
- Levit Dermatology — 1 record
- Tanta University — 1 record
Representative registered studies
Recruiting studies first, then the most advanced phases. Each identifier links to the registry record, where eligibility criteria, outcome measures and contacts are published.
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT07693244 — Exosome Therapy for Male Androgenetic Alopecia | Phase 2 | Recruiting | 120 | Zhang Han | 2026-04-30 |
| NCT07203599 — A Study on the Treatment of Androgenetic Alopecia in Young Men With Umbilical Cord Mesenchymal Stem Cell Exosomes | Phase 1, Phase 2 | Recruiting | 59 | Shenzhen People's Hospital | 2025-09-20 |
| NCT07373054 — Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Androgenic Alopecia | n/a | Recruiting | 18 | Fujian Medical University Union Hospital | 2025-11-06 |
| NCT06697080 — Umbilical Cord-derived Mesenchymal Stem Cell Exosomes on Hair Growth in Patients With Androgenetic Alopecia | n/a | Active Not Recruiting | 50 | Nanfang Hospital, Southern Medical University | 2024-06-28 |
| NCT06539273 — Exosome Treatment in Androgenetic Alopecia | Phase 3 | Completed | 30 | Yeditepe University Hospital | 2024-01-01 |
| NCT07112586 — Evaluation of Exosomes Injection in Treatment of Male Androgenetic Alopecia: Clinical and Immunohistochemical Study | Phase 1, Phase 2 | Not Yet Recruiting | 15 | Ain Shams University | 2025-08-30 |
| NCT06239207 — Efficacy and Safety of Exosomes Versus Platelet Rich Plasma in Patients of Androgenetic Alopecia | Phase 2 | Completed | 30 | Services Hospital, Lahore | 2023-09-21 |
| NCT06482541 — Efficacy and Safety Of AGE ZERO™ EXOSOMES To Treat Men and Women With Androgenetic Alopecia | Phase 1 | Unknown | 100 | Levit Dermatology | 2024-07 |
| NCT07248410 — A Split-Scalp Study Evaluating the Efficacy and Safety of Fractional Laser Therapy With and Without Exosomes in the Treatment of Androgenetic Alopecia | n/a | Not Yet Recruiting | 30 | Chang Gung Memorial Hospital | 2025-11-24 |
| NCT07776015 — Exosome Injection Versus Topical Minoxidil for Androgenetic Alopecia | n/a | Completed | 40 | Tanta University | 2023-04-20 |
What this page does and does not tell you
Treat this as a map of research activity. It tells you whether a claim has an evidence programme behind it — not whether the treatment helped anyone.
If a clinic offers you this today, the useful question is not "is there research?" but "which of these registered studies is mine part of, and if none, what evidence applies to the exact product I am being sold?" The Provider Question Builder turns that into a scored checklist.
Frequently asked
How many exosomes studies for Hair Loss & Restoration are recruiting right now?
3 of 10 registered records were listed as recruiting in the 2026-08-29 snapshot. Recruitment status changes frequently; the registry record is authoritative.
Is exosomes an approved treatment for Hair Loss & Restoration?
Registration on ClinicalTrials.gov is not approval. Approval is granted by a regulator for a specific product and indication after review of submitted evidence. 10 registered studies tell you research exists, not that a product cleared review.
How advanced is the research on exosomes for Hair Loss & Restoration?
1 of 10 records carry a Phase 3 or Phase 4 label and 3 are marked completed. Registrations run from 2023 to 2026.
Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.
Download the query data
Query totals are full API matches; status, phase and country counts describe the first up to 400 returned records per query. Query classes overlap and must not be summed as unique trials. Counts are not treatment outcomes. Snapshot: 2026-08-29. Methods and field definitions.